|
Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer Clinical research trials and Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer. Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer clinical trial. Test subjects typically receive the most effective healthcare possible for their Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer  Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer
Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer
For Condition: adenocarcinoma of the prostate,recurrent prostate cancer,stage 4 prostate cancer
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy, such as paclitaxel and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Combining thalidomide with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining paclitaxel and estramustine with thalidomide in treating patients who have progressivemetastaticandrogen-independent prostate cancer.
Details: OBJECTIVES: - Determine the maximum tolerated dose of paclitaxel and thalidomide administered with estramustine in patients with progressive metastatic androgen-independent prostate cancer. - Determine the efficacy of this regimen in these patients. - Determine the objective response rate and prostate-specific antigen response rate in patients treated with this regimen. - Determine time to disease progression, performance status, analgesic consumption, and survival of patients treated with this regimen. - Determine the toxicity of this regimen in these patients. OUTLINE: This is a phase I dose-escalation study of paclitaxel and thalidomide followed by a phase II study. - Patients receive oral estramustine three times daily on days 1-5 and 8-12, oral thalidomide once daily on days 1-21, and paclitaxel IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of paclitaxel and thalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. - Phase II: Patients receive paclitaxel, estramustine, and thalidomide as in arm I at the MTD. PROJECTED ACCRUAL: A total of 48-75 patients (18 for phase I and 30-57 for phase II) will be accrued for this study within 8-15 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma* of the prostate - Biopsy of a metastatic site allowed provided the tissue stains positive for prostate-specific antigen (PSA) - Indicator lesions need not be biopsy proven if the clinical presentation is characteristic - Nodal and/or visceral disease allowed NOTE: *Variant histologies (e.g., ductal carcinoma and small cell carcinoma) are allowed only for the phase I portion of the study - Progressive androgen-independent disease, as evidenced by the following: - Testosterone 50 ng/dL OR prior bilateral orchiectomy - Patients must continue luteinizing hormone-releasing hormone agonists to maintain castrate levels - Symptomatic progression OR rising PSA on two occasions, at least 1 week apart, with a minimum pretreatment PSA of 5 ng/mL - Progressive disease after at least 1, but no more than 2, prior chemotherapy regimens for prostate cancer in the neoadjuvant or metastatic setting (phase II only) - No CNS metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Zubrod 0-2 Life expectancy - At least 12 weeks Hematopoietic - Absolute neutrophil count 1,500/mm^3 - Platelet count 100,000/mm^3 - Hemoglobin 9.0 g/dL Hepatic - SGOT and SGPT < 2 times upper limit of normal (ULN) - Bilirubin < 2 times ULN Renal - Creatinine 2.0 mg/dL OR - Creatinine clearance 35 mL/min Cardiovascular - No clinical history of heart disease - ECG normal OR - Ejection fraction 45% by echocardiogram, MUGA, or ventriculography Other - No active or uncontrolled infection - No significant psychiatric disorder that would preclude giving informed consent - No grade 2 or greater peripheral neuropathy - No other malignancy within the past 5 years except superficial bladder cancer or basal cell skin cancer - No other serious medical illness PRIOR CONCURRENT THERAPY: Biologic therapy - More than 2 weeks since prior immunotherapy AND evidence of disease progression - More than 2 weeks since prior antiangiogenesis therapy AND evidence of disease progression Chemotherapy - See Disease Characteristics - No more than 2 prior chemotherapy* regimens for prostate cancer - More than 3 weeks since prior chemotherapy and recovered - Prior taxanes allowed NOTE: *Ketoconazole is considered chemotherapy Endocrine therapy - See Disease Characteristics - At least 4 weeks since prior flutamide or nilutamide (6 weeks for bicalutamide) AND no evidence of response or disease progression since withdrawal - No concurrent antiandrogens (e.g., flutamide, nilutamide or bicalutamide) Radiotherapy - More than 12 weeks since prior strontium chloride Sr 89 - No more than 1 prior dose of strontium chloride Sr 89 - More than 3 weeks since prior radiotherapy - No prior radiotherapy to more than 15% of the bone marrow Surgery - See Disease Characteristics - At least 2 weeks since prior surgery Other - More than 2 weeks since prior non-androgen mediated pathway therapy (e.g., epidermal growth factor receptor antagonists or farnesyl transferase inhibitors) AND evidence of disease progression - More than 2 weeks since prior herbal or alternative medicines or PC-SPES AND evidence of disease progression
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DanaiDaliani, Study Chair, M.D. Anderson Cancer Center
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4009
United States
Recruiting Danai Daliani 713-792-2830
Additional Information:
Study ID Numbers: CDR0000355825; MDA-ID-00087
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00082693
Other Recurrent Prostate Cancer Studies:
1. Vaccine Therapy in Treating Patients With Progressive Prostate Cancer
2. Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
3. Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
4. Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
5. DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
Related Studies:
Other recurrent prostate cancer Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer
|
|
|
|
|
|
|
|
